160 related articles for article (PubMed ID: 26598755)
1. Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.
Roberts MC; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes KE; Carey LA; Troester MA; Wheeler SB
J Clin Oncol; 2016 Jan; 34(2):130-8. PubMed ID: 26598755
[TBL] [Abstract][Full Text] [Related]
2. Addressing Social Determinants in the Era of Precision Medicine in Breast Cancer: Is It Sufficient to Reduce Disparities?
Freeman JQ; Huo D
Cancer Epidemiol Biomarkers Prev; 2024 May; 33(5):635-637. PubMed ID: 38689576
[TBL] [Abstract][Full Text] [Related]
3. Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.
Orucevic A; Bell JL; McNabb AP; Heidel RE
Breast Cancer Res Treat; 2017 May; 163(1):51-61. PubMed ID: 28243897
[TBL] [Abstract][Full Text] [Related]
4. Racial disparities in initiation of chemotherapy among breast cancer patients with discretionary treatment indication in the state of Georgia.
Collin LJ; Jones J; Nash R; Switchenko JM; Ward KC; McCullough LE
Breast Cancer Res Treat; 2024 Jun; 205(3):609-618. PubMed ID: 38517602
[TBL] [Abstract][Full Text] [Related]
5. Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX.
Sengupta AK; Gunda A; Malpani S; Serkad CPV; Basavaraj C; Bapat A; Bakre MM
Cancer Med; 2020 Nov; 9(21):7810-7818. PubMed ID: 33027559
[TBL] [Abstract][Full Text] [Related]
6. Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base.
Ibraheem A; Olopade OI; Huo D
Cancer; 2020 Sep; 126(17):4013-4022. PubMed ID: 32521056
[TBL] [Abstract][Full Text] [Related]
7. Benefits of introduction of Oncotype DX
Green N; Al-Allak A; Fowler C
Ann R Coll Surg Engl; 2019 Jan; 101(1):55-59. PubMed ID: 30322288
[TBL] [Abstract][Full Text] [Related]
8. Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016.
Schwedhelm TM; Rees JR; Onega T; Zipkin RJ; Schaefer A; Celaya MO; Moen EL
BMC Cancer; 2020 Sep; 20(1):847. PubMed ID: 32883270
[TBL] [Abstract][Full Text] [Related]
9. Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer.
Holowatyj AN; Cote ML; Ruterbusch JJ; Ghanem K; Schwartz AG; Vigneau FD; Gorski DH; Purrington KS
J Clin Oncol; 2018 Mar; 36(7):652-658. PubMed ID: 29341832
[TBL] [Abstract][Full Text] [Related]
10. Understanding mechanisms of racial disparities in breast cancer: an assessment of screening and regular care in the Carolina Breast Cancer Study.
Dunn MR; Metwally EM; Vohra S; Hyslop T; Henderson LM; Reeder-Hayes K; Thompson CA; Lafata JE; Troester MA; Butler EN
Cancer Causes Control; 2024 May; 35(5):825-837. PubMed ID: 38217760
[TBL] [Abstract][Full Text] [Related]
11. Association Between Ki-67 Proliferative Index and Oncotype-Dx Recurrence Score in Hormone Receptor-Positive, HER2-Negative Early Breast Cancers. A Systematic Review of the Literature.
Mooghal M; Khan MAA; Samar MR; Shaikh H; Valimohammad AT; Idrees R; Abdul Rashid Y; Sattar AK
Breast Cancer (Auckl); 2024; 18():11782234241255211. PubMed ID: 38779417
[TBL] [Abstract][Full Text] [Related]
12. Racial differences in physical activity among breast cancer survivors: implications for breast cancer care.
Hair BY; Hayes S; Tse CK; Bell MB; Olshan AF
Cancer; 2014 Jul; 120(14):2174-82. PubMed ID: 24911404
[TBL] [Abstract][Full Text] [Related]
13. Simulating the population impact of interventions to reduce racial gaps in breast cancer treatment.
Yanguela J; Jackson BE; Reeder-Hayes KE; Roberson ML; Rocque GB; Kuo TM; LeBlanc MR; Baggett CD; Green L; Laurie-Zehr E; Wheeler SB
J Natl Cancer Inst; 2024 Jun; 116(6):902-910. PubMed ID: 38281076
[TBL] [Abstract][Full Text] [Related]
14. Racial Disparities in Receipt of Guideline-Concordant Care for Early-Onset Colorectal Cancer in the United States.
Nogueira LM; May FP; Yabroff KR; Siegel RL
J Clin Oncol; 2024 Apr; 42(12):1368-1377. PubMed ID: 37939323
[TBL] [Abstract][Full Text] [Related]
15. Young Age as a Predictor of Chemotherapy Recommendation and Treatment in Breast Cancer: A National Cancer Database Study.
Graham E; Bennett K; Boselli D; Hecksher A; Schepel C; White RL; Hadzikadic-Gusic L
J Surg Res; 2024 Apr; 296():155-164. PubMed ID: 38277952
[TBL] [Abstract][Full Text] [Related]
16. Disparities in the use of screening magnetic resonance imaging of the breast in community practice by race, ethnicity, and socioeconomic status.
Haas JS; Hill DA; Wellman RD; Hubbard RA; Lee CI; Wernli KJ; Stout NK; Tosteson AN; Henderson LM; Alford-Teaster JA; Onega TL
Cancer; 2016 Feb; 122(4):611-7. PubMed ID: 26709819
[TBL] [Abstract][Full Text] [Related]
17. Racial Differences in Germline Genetic Testing Completion Among Males With Pancreatic, Breast, or Metastatic Prostate Cancers.
Shevach JW; Candelieri-Surette D; Lynch JA; Hubbard RA; Alba PR; Glanz K; Parikh RB; Maxwell KN
J Natl Compr Canc Netw; 2024 Apr; 22(4):237-243. PubMed ID: 38631387
[TBL] [Abstract][Full Text] [Related]
18. Disparities in breast cancer treatment and outcomes: biological, social, and health system determinants and opportunities for research.
Wheeler SB; Reeder-Hayes KE; Carey LA
Oncologist; 2013; 18(9):986-93. PubMed ID: 23939284
[TBL] [Abstract][Full Text] [Related]
19. Assessing Perceived Discrimination as Reported by Black and White Women Diagnosed with Breast Cancer.
Sutton AL; Hagiwara N; Perera RA; Sheppard VB
J Racial Ethn Health Disparities; 2021 Jun; 8(3):589-595. PubMed ID: 32808196
[TBL] [Abstract][Full Text] [Related]
20. A new methodology to predict the oncotype scores based on clinico-pathological data with similar tumor profiles.
Al Masry Z; Pic R; Dombry C; Devalland C
Breast Cancer Res Treat; 2024 Feb; 203(3):587-598. PubMed ID: 37926760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
